
John C L Mamo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5144193/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Attenuation of chronic tension headache frequency and severity with daily l-arginine and aged garlic extract dietary supplementation. European Journal of Clinical Nutrition, 2022, 76, 317-319.	2.9	2
2	Short-term consumption of alcohol (vodka) mixed with energy drink (AMED) attenuated alcohol-induced cerebral capillary disturbances and neuroinflammation in adult wild-type mice. Nutritional Neuroscience, 2022, 25, 2398-2407.	3.1	2
3	Efficacy of probucol on cognitive function in Alzheimer's disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study). BMJ Open, 2022, 12, e058826.	1.9	8
4	Chronic high fat feeding paradoxically attenuates cerebral capillary dysfunction and neurovascular inflammation in Senescence-Accelerated-Murine-Prone Strain 8 mice. Nutritional Neuroscience, 2021, 24, 635-643.	3.1	4
5	Chronic Intake of Energy Drinks and Their Sugar Free Substitution Similarly Promotes Metabolic Syndrome. Nutrients, 2021, 13, 1202.	4.1	6
6	Blood–brain barrier disruption and ventricular enlargement are the earliest neuropathological changes in rats with repeated sub-concussive impacts over 2Âweeks. Scientific Reports, 2021, 11, 9261.	3.3	10
7	Automated Quantitative Analysis of ex vivo Blood-Brain Barrier Permeability Using Intellesis Machine-Learning. Frontiers in Neuroscience, 2021, 15, 617221.	2.8	7
8	The Consumption of Energy Drinks Induces Blood-Brain Barrier Dysfunction in Wild-Type Mice. Frontiers in Nutrition, 2021, 8, 668514.	3.7	3
9	Sodium alginate microencapsulation improves the short-term oral bioavailability of cannabidiol when administered with deoxycholic acid. PLoS ONE, 2021, 16, e0243858.	2.5	6
10	A Systematic Review of the MDMA Model to Address Social Impairment in Autism. Current Neuropharmacology, 2021, 19, 1101-1154.	2.9	1
11	Synthesis of human amyloid restricted to liver results in an Alzheimer disease–like neurodegenerative phenotype. PLoS Biology, 2021, 19, e3001358.	5.6	42
12	Hypertriglyceridemia and Alzheimer Disease: Opening the Mind to New Therapeutic Opportunities. Clinical Chemistry, 2021, 67, 6-8.	3.2	0
13	The Effects of Chronic Consumption of Lipid-Rich and Delipidated Bovine Dairy Milk on Brown Adipose Tissue Volume in Wild-Type Mice. Nutrients, 2021, 13, 4266.	4.1	1
14	Diabetic hypertriglyceridaemia and Alzheimer's disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2021, Publish Ahead of Print, .	2.3	3
15	Genetic, environmental and biomarker considerations delineating the regulatory effects of vitamin D on central nervous system function. British Journal of Nutrition, 2020, 123, 41-58.	2.3	3
16	Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study. Scientific Reports, 2020, 10, 106.	3.3	41
17	A Systematic Review of the Valproic-Acid-Induced Rodent Model of Autism. Developmental Neuroscience, 2020, 42, 12-48.	2.0	76
18	Sample preparation with sucrose cryoprotection dramatically alters Zn distribution in the rodent hippocampus, as revealed by elemental mapping. Journal of Analytical Atomic Spectrometry, 2020, 35, 2498-2508.	3.0	19

#	Article	IF	CITATIONS
19	Chronic Consumption of Bovine Dairy Milk Attenuates Dietary Saturated Fatty Acid-Induced Blood-Brain Barrier Dysfunction. Frontiers in Nutrition, 2020, 7, 58.	3.7	3
20	Revealing differences in the chemical form of zinc in brain tissue using K-edge X-ray absorption near-edge structure spectroscopy. Metallomics, 2020, 12, 2134-2144.	2.4	8
21	Dietary saturated fats and apolipoprotein B48 levels are similarly associated with cognitive decline in healthy older aged Australians. Asia Pacific Journal of Clinical Nutrition, 2020, 29, 537-544.	0.4	1
22	Chronic Consumption of a Commercial Energy Drink Reduces Blood Pressure in Normotensive Wild-Type Mice. Frontiers in Nutrition, 2019, 6, 111.	3.7	3
23	Elemental characterisation of the pyramidal neuron layer within the rat and mouse hippocampus. Metallomics, 2019, 11, 151-165.	2.4	19
24	Multimodal Imaging Analyses of Brain Hippocampal Formation Reveal Reduced Cu and Lipid Content and Increased Lactate Content in Non-Insulin-Dependent Diabetic Mice. ACS Chemical Neuroscience, 2019, 10, 2533-2540.	3.5	10
25	The differential effects of fatty acids on enterocytic abundance of amyloid-beta. Lipids in Health and Disease, 2019, 18, 209.	3.0	21
26	Probucol prevents blood–brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. Diabetes and Vascular Disease Research, 2019, 16, 87-97.	2.0	44
27	Blood-brain barrier disturbances in diabetes-associated dementia: Therapeutic potential for cannabinoids. Pharmacological Research, 2019, 141, 291-297.	7.1	26
28	The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4Âweeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects. Drug Delivery and Translational Research, 2018, 8, 543-551.	5.8	42
29	Longitudinal Performance of Senescence Accelerated Mouse Prone-Strain 8 (SAMP8) Mice in an Olfactory-Visual Water Maze Challenge. Frontiers in Behavioral Neuroscience, 2018, 12, 174.	2.0	5
30	Sodium alginate capsulation increased brain delivery of probucol and suppressed neuroinflammation and neurodegeneration. Therapeutic Delivery, 2018, 9, 703-709.	2.2	27
31	Biospectroscopic Imaging Provides Evidence of Hippocampal Zn Deficiency and Decreased Lipid Unsaturation in an Accelerated Aging Mouse Model. ACS Chemical Neuroscience, 2018, 9, 2774-2785.	3.5	18
32	Focal plane array IR imaging at the Australian Synchrotron. Infrared Physics and Technology, 2018, 94, 85-90.	2.9	11
33	Contemporary lipidomic analytics: opportunities and pitfalls. Progress in Lipid Research, 2018, 71, 86-100.	11.6	33
34	Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance. Experimental and Clinical Endocrinology and Diabetes, 2017, 125, 28-32.	1.2	25
35	Differential regulation of sphingolipid metabolism in plasma, hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents. Journal of Neurochemistry, 2017, 141, 413-422.	3.9	5
36	Antihypertensive agents do not prevent blood–brain barrier dysfunction and cognitive deficits in dietary-induced obese mice. International Journal of Obesity, 2017, 41, 926-934.	3.4	23

JOHN C L ΜΑΜΟ

#	Article	IF	CITATIONS
37	Dietary fat and physiological determinants of plasma chylomicron remnant homoeostasis in normolipidaemic subjects: insight into atherogenic risk. British Journal of Nutrition, 2017, 117, 403-412.	2.3	9
38	A Multimodal Spectroscopic Imaging Method To Characterize the Metal and Macromolecular Content of Proteinaceous Aggregates ("Amyloid Plaquesâ€). Biochemistry, 2017, 56, 4107-4116.	2.5	55
39	FTIR studies of the similarities between pathology induced protein aggregation in vivo and chemically induced protein aggregation ex vivo. Vibrational Spectroscopy, 2017, 91, 68-76.	2.2	24
40	Blood-Brain Barrier Dysfunction Precedes Cognitive Decline and Neurodegeneration in Diabetic Insulin Resistant Mouse Model: An Implication for Causal Link. Frontiers in Aging Neuroscience, 2017, 9, 399.	3.4	108
41	Differential Effects of High-Protein Diets Derived from Soy and Casein on Blood–Brain Barrier Integrity in Wild-type Mice. Frontiers in Nutrition, 2017, 4, 35.	3.7	13
42	Plasma triglyceride and high density lipoprotein cholesterol are poor surrogate markers of pro-atherogenic chylomicron remnant homeostasis in subjects with the metabolic syndrome. Lipids in Health and Disease, 2016, 15, 169.	3.0	8
43	The Effects of Long-Term Saturated Fat Enriched Diets on the Brain Lipidome. PLoS ONE, 2016, 11, e0166964.	2.5	30
44	The Association of Vitamin D Status with Dyslipidaemia and Biomarkers of Endothelial Cell Activation in Older Australians. Nutrients, 2016, 8, 457.	4.1	6
45	Biostatistical analysis of quantitative immunofluorescence microscopy images. Journal of Microscopy, 2016, 264, 321-333.	1.8	3
46	Resolution of non-psychogenic epileptic-like seizures utilizing a vasodilatory and anti-inflammatory dietary intervention. European Journal of Clinical Nutrition, 2016, 70, 1210-1211.	2.9	0
47	Pharmacological modulation of dietary lipid-induced cerebral capillary dysfunction: Considerations for reducing risk for Alzheimer's disease. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 166-183.	6.1	11
48	Serum 25-hydroxyvitamin D is associated with reduced verbal episodic memory in healthy, middle-aged and older adults. European Journal of Nutrition, 2016, 55, 1503-1513.	3.9	22
49	The effect of diesel exhaust exposure on blood–brain barrier integrity and function in a murine model. Journal of Applied Toxicology, 2015, 35, 41-47.	2.8	30
50	Validity of Two New Brief Instruments to Estimate Vegetable Intake in Adults. Nutrients, 2015, 7, 6688-6699.	4.1	4
51	Nicotine Attenuates Disruption of Blood–Brain Barrier Induced by Saturated-Fat Feeding in Wild-Type Mice. Nicotine and Tobacco Research, 2015, 17, 1436-1441.	2.6	14
52	Blood–brain barrier dysfunction developed during normal aging is associated with inflammation and loss of tight junctions but not with leukocyte recruitment. Immunity and Ageing, 2015, 12, 2.	4.2	221
53	Hypertriglyceridemic subjects exhibit an accumulation of small dense chylomicron particles in the fasting state. Atherosclerosis, 2015, 243, 236-241.	0.8	7
54	The Vitamin D, Ionised Calcium and Parathyroid Hormone Axis of Cerebral Capillary Function: Therapeutic Considerations for Vascular-Based Neurodegenerative Disorders. PLoS ONE, 2015, 10, e0125504.	2.5	13

#	Article	IF	CITATIONS
55	Neuropsychological Performance Is Positively Associated with Plasma Albumin in Healthy Adults. Neuropsychobiology, 2014, 69, 31-38.	1.9	2
56	Long-term probucol therapy continues to suppress markers of neurovascular inflammation in a dietary induced model of cerebral capillary dysfunction. Lipids in Health and Disease, 2014, 13, 91.	3.0	23
57	Vitamin D & endothelial function. Indian Journal of Medical Research, 2014, 140, 483-90.	1.0	8
58	Nutraceutical agents with anti-inflammatory properties prevent dietary saturated-fat induced disturbances in blood–brain barrier function in wild-type mice. Journal of Neuroinflammation, 2013, 10, 73.	7.2	53
59	Probucol prevents blood–brain barrier dysfunction in wildâ€type mice induced by saturated fat or cholesterol feeding. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 45-52.	1.9	46
60	Adjustment of ionized calcium concentration for serum pH is not a valid marker of calcium homeostasis: implications for identifying individuals at risk of calcium metabolic disorders. Annals of Clinical Biochemistry, 2013, 50, 224-229.	1.6	15
61	Aging-Related Changes in Blood-Brain Barrier Integrity and the Effect of Dietary Fat. Neurodegenerative Diseases, 2013, 12, 125-135.	1.4	51
62	The Serum Concentration of the Calcium Binding Protein S100B is Positively Associated with Cognitive Performance in Older Adults. Frontiers in Aging Neuroscience, 2013, 5, 61.	3.4	22
63	Consumption of low doses of fat prevents the postprandial rise in chylomicron particle concentration and remnant accumulation in healthy normolipidaemic males. Journal of Nutritional Science, 2012, 1, e4.	1.9	2
64	A Diet Enriched in Docosahexanoic Acid Exacerbates Brain Parenchymal Extravasation of Apo B Lipoproteins Induced by Chronic Ingestion of Saturated Fats. International Journal of Vascular Medicine, 2012, 2012, 1-8.	1.0	12
65	Understanding Postprandial Inflammation and Its Relationship to Lifestyle Behaviour and Metabolic Diseases. International Journal of Vascular Medicine, 2012, 2012, 1-11.	1.0	72
66	Novel Aspects of Nonfasting Lipemia in relation to Vascular Biology. International Journal of Vascular Medicine, 2012, 2012, 1-2.	1.0	4
67	ApoA-1 infusion reduces arterial cholesterol and myocardial lesions in a rat model of cardiac dysfunction and insulin resistance. Atherosclerosis, 2012, 222, 402-408.	0.8	22
68	Restoration of dietary-fat induced blood–brain barrier dysfunction by anti-inflammatory lipid-modulating agents. Lipids in Health and Disease, 2012, 11, 117.	3.0	47
69	Probucol Suppresses Enterocytic Accumulation of Amyloidâ€Î² Induced by Saturated Fat and Cholesterol Feeding. Lipids, 2012, 47, 27-34.	1.7	22
70	Colocalisation of plasma derived apo B lipoproteins with cerebral proteoglycans in a transgenic-amyloid model of Alzheimer's disease. Neuroscience Letters, 2011, 492, 160-164.	2.1	15
71	Increased risk of cardiovascular disease in Type 1 diabetes: arterial exposure to remnant lipoproteins leads to enhanced deposition of cholesterol and binding to glycated extracellular matrix proteoglycans. Diabetic Medicine, 2011, 28, 61-72.	2.3	31
72	Tailored, iterative, printed dietary feedback is as effective as group education in improving dietary behaviours: results from a randomised control trial in middle-aged adults with cardiovascular risk factors. International Journal of Behavioral Nutrition and Physical Activity, 2011, 8, 43.	4.6	37

JOHN C L ΜΑΜΟ

#	Article	IF	CITATIONS
73	Differential effects of dietary fatty acids on the cerebral distribution of plasma-derived apo B lipoproteins with amyloid-β. British Journal of Nutrition, 2010, 103, 652-662.	2.3	80
74	Dietary fats, cerebrovasculature integrity and Alzheimer's disease risk. Progress in Lipid Research, 2010, 49, 159-170.	11.6	89
75	Post-prandial lipid metabolism, lipid-modulating agents and cerebrovascular integrity: Implications for dementia risk. Atherosclerosis Supplements, 2010, 11, 49-54.	1.2	37
76	Three-dimensional colocalization analysis of plasma-derived apolipoprotein B with amyloid plaques in APP/PS1 transgenic mice. Histochemistry and Cell Biology, 2009, 131, 661-666.	1.7	43
77	Amyloid-β colocalizes with apolipoprotein B in absorptive cells of the small intestine. Lipids in Health and Disease, 2009, 8, 46.	3.0	37
78	The effect of exogenous cholesterol and lipid-modulating agents on enterocytic amyloid-β abundance. British Journal of Nutrition, 2009, 101, 340-347.	2.3	17
79	Three-dimensional immunofluorescent double labelling using polyclonal antibodies derived from the same species: enterocytic colocalization of chylomicrons with Golgi apparatus. Histochemistry and Cell Biology, 2008, 129, 779-784.	1.7	16
80	Synergistic effects of high fat feeding and apolipoprotein E deletion on enterocytic amyloid-beta abundance. Lipids in Health and Disease, 2008, 7, 15.	3.0	19
81	Chylomicron amyloid-beta in the aetiology of Alzheimer's disease. Atherosclerosis Supplements, 2008, 9, 19-25.	1.2	37
82	Plasma lipoprotein β-amyloid in subjects with Alzheimer's disease or mild cognitive impairment. Annals of Clinical Biochemistry, 2008, 45, 395-403.	1.6	53
83	Polyphenoloxidase and Its Thermal Deactivation in Western Rock Lobster (Panulirus cygnus) Processing. Journal of Aquatic Food Product Technology, 2007, 16, 87-102.	1.4	2
84	Prior exercise does not affect chylomicron particle number following a mixed meal of moderate fat content. Lipids in Health and Disease, 2007, 6, 8.	3.0	17
85	β-Amyloid or its precursor protein is found in epithelial cells of the small intestine and is stimulated by high-fat feeding. Journal of Nutritional Biochemistry, 2007, 18, 279-284.	4.2	75
86	The effect of chronic consumption of red wine on cardiovascular disease risk factors in postmenopausal women. Atherosclerosis, 2006, 185, 438-445.	0.8	74
87	An investigation by electron microscopy of chylomicron remnant uptake by human monocyte-derived macrophages. Atherosclerosis, 2006, 188, 251-259.	0.8	12
88	Comparison of isocaloric very low carbohydrate/high saturated fat and high carbohydrate/low saturated fat diets on body composition and cardiovascular risk. Nutrition and Metabolism, 2006, 3, 7.	3.0	109
89	Effect of an acute hyperinsulinaemic clamp on post-prandial lipaemia in subjects with insulin resistance. European Journal of Clinical Investigation, 2006, 36, 489-496.	3.4	11
90	The effect of chronic consumption of red wine polyphenols on vascular function in postmenopausal women. European Journal of Clinical Nutrition, 2006, 60, 740-745.	2.9	34

#	Article	IF	CITATIONS
91	The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin-resistant subjects. Diabetes, Obesity and Metabolism, 2005, 7, 381-389.	4.4	32
92	A low-protein diet exacerbates postprandial chylomicron concentration in moderately dyslipidaemic subjects in comparison to a lean red meat protein-enriched diet. European Journal of Clinical Nutrition, 2005, 59, 1142-1148.	2.9	27
93	The immunodetection of lipoprotein-bound amyloid-β is attenuated because of the presence of lipids. Annals of Clinical Biochemistry, 2005, 42, 70-72.	1.6	5
94	Could iodine be effective in the treatment of human immunodeficiency virus and AIDS-associated opportunistic infections?. International Journal of Infectious Diseases, 2005, 9, 292-293.	3.3	4
95	Arterial Permeability and Efflux of Apolipoprotein B–Containing Lipoproteins Assessed by In Situ Perfusion and Three-Dimensional Quantitative Confocal Microscopy. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 2162-2167.	2.4	88
96	Polyphenolics and fat absorption. International Journal of Obesity, 2004, 28, 324-326.	3.4	31
97	Red wine polyphenolics suppress the secretion and the synthesis of Apo B48 from human intestinal Caco-2 cells. BioFactors, 2004, 22, 181-183.	5.4	7
98	Insulin decreases the secretion of apoB-100 from hepatic HepG2 cells but does not decrease the secretion of apoB-48 from intestinal CaCo-2 cells. Journal of Biomedical Science, 2004, 11, 789-798.	7.0	3
99	The effect of acute red wine polyphenol consumption on postprandial lipaemia in postmenopausal women. Atherosclerosis, 2004, 177, 401-408.	0.8	51
100	The acute effects of olive oil v. cream on postprandial thermogenesis and substrate oxidation in postmenopausal women. British Journal of Nutrition, 2004, 91, 245-252.	2.3	79
101	Insulin Decreases the Secretion of apoB-100 from Hepatic HepG2 Cells but Does Not Decrease the Secretion of apoB-48 from Intestinal CaCo-2 Cells. Journal of Biomedical Science, 2004, 11, 789-798.	7.0	1
102	Identification of Lipoproteins of Intestinal Origin in Human Atherosclerotic Plaque. Clinical Chemistry and Laboratory Medicine, 2003, 41, 792-5.	2.3	90
103	Chylomicron remnant metabolism studied with a new breath test in postmenopausal women with and without typeÂ2 diabetes mellitus. Clinical Endocrinology, 2003, 58, 415-420.	2.4	37
104	Heat-induced Activation of Polyphenoloxidase in Western Rock Lobster (Panulirus cygnus) Hemolymph: Implications for Heat Processing. Journal of Food Science, 2003, 68, 1928-1932.	3.1	20
105	Effect of atorvastatin on apolipoprotein B48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism: Clinical and Experimental, 2003, 52, 1279-1286.	3.4	29
106	Effect of weight loss on postprandial lipemia and low-density lipoprotein receptor binding in overweight men. Metabolism: Clinical and Experimental, 2003, 52, 136-141.	3.4	50
107	Intimal Retention of Cholesterol Derived From Apolipoprotein B100– and Apolipoprotein B48–Containing Lipoproteins in Carotid Arteries of Watanabe Heritable Hyperlipidemic Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1595-1600.	2.4	115
108	The incorporation and metabolism of amyloid-β into chylomicron-like lipid emulsions. Journal of Alzheimer's Disease, 2003, 5, 179-188.	2.6	29

#	Article	IF	CITATIONS
109	Red Wine Polyphenolics Increase LDL Receptor Expression and Activity and Suppress the Secretion of ApoB100 from Human HepG2 Cells. Journal of Nutrition, 2003, 133, 700-706.	2.9	140
110	Arterial retention of apolipoprotein B48- and B100-containing lipoproteins in atherogenesis. Current Opinion in Lipidology, 2002, 13, 461-470.	2.7	173
111	Cholesterol esters regulate apoB48 secretion in CaCo2 cells. Atherosclerosis, 2002, 161, 55-63.	0.8	26
112	The effect of Puerariae radix on lipoprotein metabolism in liver and intestinal cells. BMC Complementary and Alternative Medicine, 2002, 2, 12.	3.7	16
113	Effect of dietary cholesterol oxidation products on the plasma clearance of chylomicrons in the rat. Lipids, 2002, 37, 455-462.	1.7	10
114	Effect of Simvastatin on markers of triglyceride-rich lipoproteins in familial hypercholesterolaemia. European Journal of Clinical Investigation, 2002, 32, 493-499.	3.4	10
115	Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clinical Chemistry, 2002, 48, 278-83.	3.2	21
116	Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test. Journal of Lipid Research, 2002, 43, 706-12.	4.2	30
117	Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression?. American Journal of Physiology - Endocrinology and Metabolism, 2001, 281, E626-E632.	3.5	90
118	Binding and uptake of chylomicron remnants by primary and THP-1 human monocyte-derived macrophages: determination of binding proteins. Clinical Science, 2001, 101, 111-119.	4.3	21
119	Elevated apolipoprotein B-48 and remnant-like particle-cholesterol in heterozygous familial hypercholesterolaemia. European Journal of Clinical Investigation, 2001, 31, 113-117.	3.4	36
120	Chylomicron remnant metabolism in familial dyslipidemias studied with a remnant-like emulsion breath test. Journal of Lipid Research, 2001, 42, 710-5.	4.2	21
121	Binding and uptake of chylomicron remnants by primary and THP-1 human monocyte-derived macrophages: determination of binding proteins. Clinical Science, 2001, 101, 111-9.	4.3	8
122	Chylomicron-remnant-induced foam cell formation and cytotoxicity: a possible mechanism of cell death in atherosclerosis. Clinical Science, 2000, 98, 183-192.	4.3	50
123	Detection of LDL Receptor by Ligand Blotting with Chylomicron Remnants Labelled with Colloidal Gold. Annals of Clinical Biochemistry, 2000, 37, 471-478.	1.6	6
124	Islet Amyloid Polypeptide (Amylin) Modulates Chylomicron Metabolism In Rats. Clinical and Experimental Pharmacology and Physiology, 2000, 27, 345-351.	1.9	7
125	Arterial intimal retention of pro-atherogenic lipoproteins in insulin deficient rabbits and rats. Atherosclerosis, 2000, 149, 315-322.	0.8	29
126	Detection of LDL receptor by ligand blotting with chylomicron remnants labelled with colloidal gold. Annals of Clinical Biochemistry, 2000, 37, 471-478.	1.6	2

#	Article	IF	CITATIONS
127	Chylomicron-remnant-induced foam cell formation and cytotoxicity: a possible mechanism of cell death in atherosclerosis. Clinical Science, 2000, 98, 183-92.	4.3	9
128	Post-prandial chylomicron response may be predicted by a single measurement of plasma apolipoprotein B48 in the fasting state. European Journal of Clinical Investigation, 1999, 29, 204-209.	3.4	69
129	Postprandial dyslipidaemia in a nutshell: food for thought. Australian and New Zealand Journal of Medicine, 1998, 28, 816-823.	O.5	13
130	Accumulation of chylomicron remnants in homozygous subjects with familial hypercholesterolaemia. European Journal of Clinical Investigation, 1998, 28, 379-384.	3.4	48
131	Retention of fluorescentâ€labelled chylomicron remnants within the intima of the arterial wall — evidence that plaque cholesterol may be derived from postâ€prandial lipoproteins. European Journal of Clinical Investigation, 1998, 28, 497-503.	3.4	134
132	Retention of chylomicron remnants by arterial tissue; importance of an efficient clearance mechanism from plasma. Atherosclerosis, 1998, 141, S63-S69.	0.8	95
133	Nutrition and therapeutics. Current Opinion in Lipidology, 1997, 8, U15-U17.	2.7	0
134	A Highly Sensitive Assay for Quantitation of Apolipoprotein B48 Using an Antibody to Human Apolipoprotein B and Enhanced Chemiluminescence. Annals of Clinical Biochemistry, 1997, 34, 185-189.	1.6	52
135	Phagocytic Degradation of Chylomicron Remnants by Fibroblasts from Subjects with Homozygous Familial Hypercholesterolemia. Clinical Science, 1997, 92, 197-203.	4.3	6
136	Binding and uptake of chylomicron remnants by cultured arterial smooth muscle cells from normal and Watanabe-heritable-hyperlipidemic rabbits. Lipids and Lipid Metabolism, 1997, 1346, 212-220.	2.6	5
137	IS ATHEROSCLEROSIS EXCLUSIVELY A POSTPRANDIAL PHENOMENON? Clinical and Experimental Pharmacology and Physiology, 1997, 24, 288-293.	1.9	24
138	Regulation of cholesterol synthesis and esterification in primary cultures of macrophages following uptake of Chylomicron remnants. IUBMB Life, 1997, 41, 33-39.	3.4	7
139	Absorption of dietary cholesterol oxidation products and incorporation into rat lymph chylomicrons. Lipids, 1997, 32, 887-893.	1.7	69
140	Separation and quantification of apolipoprotein B-48 and other apolipoproteins by dynamic sieving capillary electrophoresis. Journal of Lipid Research, 1997, 38, 410-414.	4.2	15
141	Separation and quantification of apolipoprotein B-48 and other apolipoproteins by dynamic sieving capillary electrophoresis. Journal of Lipid Research, 1997, 38, 410-4.	4.2	7
142	Degradation of Chylomicron Remnants by Macrophages Occurs via Phagocytosis. Biochemistry, 1996, 35, 10210-10214.	2.5	39
143	Killing of Arterial Smooth Muscle Cells by Chylomicron Remnants. Biochemical and Biophysical Research Communications, 1996, 220, 68-71.	2.1	14
144	Arterial fatty lesions have increased uptake of chylomicron remnants but not low-density lipoproteins. Coronary Artery Disease, 1996, 7, 239-45.	0.7	41

JOHN C L ΜΑΜΟ

#	Article	IF	CITATIONS
145	Kinetics and uptake in vivo of oxidatively modified lymph chylomicrons. American Journal of Physiology - Renal Physiology, 1995, 268, G709-G716.	3.4	6
146	Lipid and apolipoprotein B48 transport in mesenteric lymph and the effect of hyperphagia on the clearance of chylomicron-like emulsions in insulin-deficient rats. Diabetologia, 1994, 37, 238-246.	6.3	61
147	CLEARANCE OF CHYLOMICRON-LIKE LIPID EMULSIONS IS INCREASED IN NORMAL RABBITS BUT NOT IN HETEROZYGOUS WATANABE HERITABLE HYPERLIPIDAEMIC RABBITS FOLLOWING TREATMENT WITH CHOLESTYRAMINE OR PRAVASTATIN. Clinical and Experimental Pharmacology and Physiology, 1994, 21, 687-694.	1.9	3
148	Hyperlipidemia in streptozocin-diabetic hamsters as a model for human insulin-deficient diabetes: Comparison to streptozocin-diabetic rats. Metabolism: Clinical and Experimental, 1994, 43, 299-305.	3.4	28
149	Chylomicrons or their remnants penetrate rabbit thoracic aorta as efficiently as do smaller macromolecules, including low-density lipoprotein, high-density lipoprotein, and albumin. Coronary Artery Disease, 1994, 5, 695-706.	0.7	104
150	Effect of probucol on plasma clearance and organ uptake of chylomicrons and VLDLs in normal and diabetic rats Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993, 13, 231-239.	3.9	34
151	Effects of sphingomyelin and phosphatidylcholine acyl chains on the clearance of triacylglycerol-rich lipoproteins from plasma. Studies with lipid emulsions in rats. Lipids and Lipid Metabolism, 1992, 1126, 65-72.	2.6	41
152	Hypertriglyceridemia is exacerbated by slow lipolysis of triacylglycerol-rich lipoproteins in fed but not fasted streptozotocin diabetic rats. Lipids and Lipid Metabolism, 1992, 1128, 132-138.	2.6	33
153	Correlation of insulin deficiency and hypertriglyceridemia in diabetic rats. Diabetes Research and Clinical Practice, 1991, 12, 173-180.	2.8	19
154	Defective plasma clearance of chylomicron-like lipid emulsions in Watanabe heritable hyperlipidemic rabbits. Lipids and Lipid Metabolism, 1991, 1081, 241-245.	2.6	28
155	Partial characterization of the fructose-induced defect in very-low-density lipoprotein triglyceride metabolism. Metabolism: Clinical and Experimental, 1991, 40, 888-893.	3.4	42
156	Effects of hypothyroidism on the metabolism of lipid emulsion models of triacylglycerol-rich lipoproteins in rats. Biochemical Journal, 1991, 273, 375-381.	3.7	12
157	Chylomicron-remnant clearance in homozygote and heterozygote Watanabe-heritable-hyperlipidaemic rabbits is defective. Lack of evidence for an independent chylomicron-remnant receptor. Biochemical Journal, 1991, 276, 381-386.	3.7	77
158	Comparison of the Isotopical Tracer and the Triton WR 1339 Methods for Triglyceride Kinetics in Carbohydrate-fed Rats. Journal of Nutritional Science and Vitaminology, 1990, 36, 399-409.	0.6	11
159	Clycation of very low density lipoprotein from rat plasma impairs its catabolism. Diabetologia, 1990, 33, 339-345.	6.3	51
160	Effect of acute hyperglycemia on plasma triglyceride concentration and triglyceride secretion rate in non-fasted rats. Diabetes Research and Clinical Practice, 1990, 9, 231-238.	2.8	11
161	Catabolic defect of triglyceride is associated with abnormal very-low-density lipoprotein in experimental nephrosis. Metabolism: Clinical and Experimental, 1990, 39, 101-107.	3.4	48
162	Impaired very low-density lipoprotein-triglyceride catabolism in acute and chronic fructose-fed rats. American Journal of Physiology - Endocrinology and Metabolism, 1989, 256, E559-E565.	3.5	19

#	Article	IF	CITATIONS
163	Plasma triacylglycerol secretion in sheep. Lipids and Lipid Metabolism, 1983, 753, 272-275.	2.6	10